|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600121084 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-25 11:11:17 |
|
注册时间: Date of Registration: |
2026-03-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一次性宫腔镜及刨削系统临床验证方案 |
|
Public title: |
Clinical Validation Protocol for Disposable Hysteroscopy and Shaving System |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一次性宫腔镜及刨削系统临床验证方案 |
|
Scientific title: |
Clinical Validation Protocol for Disposable Hysteroscopy and Shaving System |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
高婷 |
研究负责人: |
高婷 |
|
Applicant: |
Gao Ting |
Study leader: |
Gao Ting |
|
申请注册联系人电话: Applicant telephone: |
+86 138 5517 1596 |
研究负责人电话:
Study leader's |
+86 138 5517 1596 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
gaoting72@163.com |
研究负责人电子邮件: Study leader's E-mail: |
gaoting72@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽省合肥市政务?化新区天鹅路1号 |
研究负责人通讯地址: |
安徽省合肥市政务?化新区天鹅路1号 |
|
Applicant address: |
No.1, Swan Road, New Administrative and Cultural District, Hefei City, Anhui Province, China |
Study leader's address: |
No.1, Swan Road, New Administrative and Cultural District, Hefei City, Anhui Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国科学技术?学附属第?医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of the University of Science and Technology of China |
||
|
研究负责人所在单位: |
中国科学技术?学附属第?医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of the University of Science and Technology of China |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026伦审第71号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国科学技术?学附属第?医院医学研究伦理委员会 |
||
|
Name of the ethic committee: |
Medical Research Ethics Committee of the First Affiliated Hospital of University of Science and Technology of China |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-28 00:00:00 | ||
|
伦理委员会联系人: |
沈爱宗 |
||
|
Contact Name of the ethic committee: |
Shen Aizong |
||
|
伦理委员会联系地址: |
安徽省合肥市庐阳区庐江路17号 |
||
|
Contact Address of the ethic committee: |
No.17 Lujiang Road, Luyang District, Hefei City, Anhui Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 551 6228 2931 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国科学技术?学附属第?医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of the University of Science and Technology of China |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省合肥市政务?化新区天鹅路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1, Swan Road, New Administrative and Cultural District, Hefei City, Anhui Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
杭州微新医疗科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hangzhou Micro-inno?Medical Technology?Co., Ltd |
||||||||||||||||||||||
|
研究疾病: |
宫腔疾病 |
||||||||||||||||||||||
|
Target disease: |
Uterine Cavity Diseases |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
初步评价一次性电子宫腔成像导管、一次性宫腔镜组织切割器及其动力系统在临床使用中的安全性与有效性,为产品性能提供临床数据支持。 |
||||||||||||||||||||||
|
Objectives of Study: |
The primary evaluation assesses the safety and efficacy of a disposable electronic uterine cavity imaging catheter, a disposable uterine cavity endoscope tissue dissector, and its power system in clinical use, providing clinical data support for product performance. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
同时需满足以下所有条件方可入组: 1.年龄18~65岁之间; 2.有宫腔镜手术指征,如子宫内膜息肉(直径≤3cm)、黏膜下肌瘤(直径≤2cm)、宫腔粘连等; 3.无宫腔镜手术禁忌症; 4.患者本人或其监护人充分了解本试验的受益和风险,仍愿意参与,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
To be eligible for inclusion in the study, the following conditions must be met: 1. Age between 18 and 65 years old; 2. Indication for endometrial surgery, such as endometrial polyps (diameter <= 3 cm), submucosal myomas (diameter <= 2 cm), or adhesions in the uterine cavity; 3. Absence of contraindications for endometrial surgery; 4. The participant or their legal guardian has a thorough understanding of the benefits and risks of the trial, is still willing to participate, and has signed an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
符合以下任意一条,则不能入选: 1.月经期或活动性子宫大量出血(出血量大于月经量)者; 2.凝血功能障碍者; 3.不能配合膀胱截石位者; 4.妊娠期或哺乳期者; 5.急性生殖道或盆腔炎症; 6.合并宫颈恶性肿瘤、生殖道结核未经系统抗结核治疗者; 7.合并各系统严重疾病不能耐受手术者,包括但不限于肝肾功能不全、心肺功能不全者; 8.参加过其它药物或医疗器械临床试验; 9.研究者认为不适宜参加本临床试验的受试者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
The following conditions must be met for an individual to be ineligible: 1. Suffering from menstruation or significant bleeding from an active uterus (bleeding volume greater than menstrual flow); 2. Having a clotting disorder; 3. Unable to comply with the lithotomy position for the bladder; 4. Pregnant or breastfeeding; 5. Acute genital or pelvic inflammation; 6. Co-existing cervical malignancy or untreated genital tuberculosis; 7. Co-existing severe conditions in various systems that make surgery intolerable, including but not limited to hepatic or renal insufficiency, cardiac or pulmonary dysfunction; 8. Having participated in clinical trials involving other medications or medical devices; 9. The investigator deems the participant unsuitable for participation in this clinical trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-15 00:00:00至 To 2026-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-01 00:00:00 至 To 2026-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不涉及 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究完成后,学术?章发布后,在申请共享数据者合理的要求下,可以联系项?负责?共享已经屏蔽了敏感信息的数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the research is completed and the academic article is published, under reasonable requests from those applying to share the data, one can contact the project leader to share the data that has already been stripped of sensitive information. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集有专?的病例收集表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is done through a dedicated case collection form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |